HC Wainwright Reiterates Buy Rating for Telix Pharmaceuticals (NASDAQ:TLX)

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 162.47% from the company’s previous close.

Other equities analysts have also issued research reports about the stock. Canaccord Genuity Group raised shares of Telix Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 6th. Wall Street Zen lowered Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. UBS Group decreased their target price on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 23rd. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Telix Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Stock Performance

NASDAQ TLX opened at $7.62 on Wednesday. The stock’s 50-day moving average price is $8.48 and its two-hundred day moving average price is $10.42. Telix Pharmaceuticals has a 1 year low of $7.16 and a 1 year high of $30.36.

Hedge Funds Weigh In On Telix Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers lifted its position in shares of Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after buying an additional 1,392 shares during the last quarter. IHT Wealth Management LLC acquired a new position in Telix Pharmaceuticals during the second quarter valued at approximately $213,000. Blair William & Co. IL acquired a new position in Telix Pharmaceuticals during the second quarter valued at approximately $217,000. Private Advisor Group LLC raised its position in shares of Telix Pharmaceuticals by 67.3% in the third quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock valued at $403,000 after purchasing an additional 16,945 shares during the period. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the second quarter worth $297,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.